AGS Health Limited

This section provides an overview of the U.S. healthcare landscape, highlighting macroeconomic trends and structural drivers within the sector. The U.S. economy is projected to remain the world's largest, with its nominal GDP expected to grow significantly. The U.S. healthcare sector is experiencing structural expansion due to factors such as an aging population, a high burden of chronic diseases, and increasing insurance coverage. Furthermore, healthcare costs per service are rising due to advanced diagnostics and treatment pathways, which puts pressure on operational and financial aspects of the ecosystem.

The section discusses various trends in the U.S. healthcare landscape, including the increasing integration of technology into healthcare delivery, the shift towards alternative and decentralized care models like telemedicine and home-based care, and the complex structure of the multi-stakeholder ecosystem. It details how different stakeholders—patients, providers, clearinghouses, and payers—interact through clinical and administrative exchanges, alongside financial settlement processes, which are highly interconnected. The text further outlines the layered financing structure where various sources fund healthcare services and flow through different payers before reaching providers.

This section details the various components of the Revenue Cycle Management (RCM) process, which is divided into front-end, mid-cycle, and back-end activities. The front-end covers pre-service functions such as patient access, eligibility verification, and financial clearance. The mid-cycle involves clinical, coding, and revenue integrity tasks, including care management, coding, and charge capture. The back-end focuses on claim submission, payment reconciliation, denial resolution, and patient collections. The text also discusses structural factors impacting RCM, such as margin pressure, capital constraints, a war for talent, increasing coding complexity, clinical burnout, payer-provider abrasion, and technology fragmentation.

The section discusses the challenges and evolution of Revenue Cycle Management (RCM) within the healthcare sector, highlighting the tension between administrative burden and the need for financial sustainability. It details how RCM has moved from manual processes to technology-enabled frameworks, emphasizing the shift towards outsourced and offshore delivery models to address staffing shortages. Furthermore, the text covers the integration of advanced AI and Generative AI into RCM to improve accuracy, alongside critical concerns regarding data security and compliance.

The analysis covers various segments of the Revenue Cycle Management (RCM) market, detailing the split between hospitals, physician practices, and other healthcare service providers. The RCM market shows a growing trend towards software adoption, where software's role is expanding despite services remaining the majority of spend. The outsourced RCM segment is expanding rapidly, driven by cost pressures, increased complexity in payer policies, and the need for specialized talent. Furthermore, the market structure indicates a shift towards offshoring in RCM delivery to capitalize on cost advantages and leverage technology for efficiency.

The company offers end-to-end coverage across the revenue cycle value chain, spanning from patient access to revenue realization, utilizing a technology-first operating model that combines proprietary automation tools, AI-driven platforms, and analytics. This technology integration is significant, accounting for approximately 19.2% of total revenue in FY 2026, and the company leverages a global delivery model across multiple countries. The company has strengthened its technology stack through targeted acquisitions, and its competitive positioning is evaluated against peers based on capability, customer focus, operating model, and delivery footprint.

The company, AGS Health Limited, is a leading technology-first Revenue Cycle Management (RCM) solutions provider that serves U.S. healthcare providers through a comprehensive platform integrating AI-driven solutions, data analytics, and specialized global delivery capabilities. The company contracts directly with U.S.-based health systems, hospitals, and physician groups to optimize revenue cycle operations across patient access, clinical documentation, billing, and collections. The RCM scope covers the entire patient journey, from scheduling to final payment collection, encompassing front-end, mid-cycle, and back-end processes. The market for U.S. RCM is experiencing substantial growth, and the company is positioned to address the demand for specialized RCM solutions.

The company provides comprehensive, AI-enabled SaaS offerings and technology-first solutions across approximately 80% of the U.S. healthcare provider revenue cycle processes. Their offerings are built on a proprietary five-layer AI platform utilizing 29 NLP and AI models. The business model focuses on achieving non-linear revenue growth by leveraging operational efficiencies, automation, and a shift towards non-FTE linked pricing, supported by strong customer relationships. The company interfaces with numerous U.S. Electronic Health Record (EHR) platforms, which is critical for ensuring accurate claims processing and reimbursement. The company operates a global delivery footprint across India, the U.S., the Philippines, and Mexico.

The company offers front-end operations focused on optimizing patient access and pre-service functions, including financial clearance and insurance verification, handling approximately 49 million appointments annually with high verification accuracy. In mid-cycle functions, the company provides autonomous coding solutions powered by AI and machine learning to ensure accurate coding and charge capture, processing about 81 million charts annually. For back-end operations, they maximize revenue realization by managing accounts receivable, including denials and appeals, processing over US$64 billion in accounts receivable annually. The company distinguishes itself by combining AI and automation with RCM domain expertise, utilizing proprietary platforms built on a five-layer architecture, and has developed 29 proprietary AI and NLP models.

The company leverages its SaaS products across the entire Revenue Cycle Management (RCM) value chain, utilizing technology to deliver measurable customer outcomes. The company has received multiple awards for efficiency improvements in document handling and automation. It operates a global delivery model across four countries, with specialized operations in India, the U.S., the Philippines, and Mexico, to provide diverse capabilities. The company boasts a strong financial profile, showing significant revenue growth and improved profitability margins compared to industry benchmarks, largely due to cost advantages from offshore delivery. The business model emphasizes non-linear revenue growth driven by automation, productivity gains, and high customer retention.

The company demonstrates the ability to rapidly deploy integrated, multi-function delivery models, expanding engagements from single-function to multi-function partnerships within 12 months. The company intends to maintain its technology leadership in the Revenue Cycle Management (RCM) industry by investing in AI, Machine Learning, and NLP to capture market share in technology spend. Key investment areas include autonomous coding, prior authorization, denials management, and payment optimization. The company is also developing capabilities to support the transition to value-based care models through developments in risk adjustment coding and alternative payment model analytics. Furthermore, the company plans to pursue strategic partnerships to enhance platform interoperability and accelerate automation development.

The company offers integrated solutions designed to optimize end-to-end performance across various segments of the revenue cycle by coordinating workflows through proprietary internal technology tools. These tools enable continuous improvement by providing feedback across front-end, mid-cycle, and back-end teams. The platform includes systems for intelligent allocation, productivity management, quality monitoring, and an AI assistant to guide operations staff. The company operates a global delivery model spanning four countries and 10 capability centers, with headquarters in both India and the United States, to ensure high-quality, cost-effective solutions with geographic redundancy. The technology platform is built on a five-layer architecture, incorporating data foundations, automation, intelligence, autonomous AI, and generative AI layers to power its AI-enabled products.

The company operates a global go-to-market organization that manages the full customer lifecycle through specialized functional teams, integrating marketing, sales, implementation, and customer success across healthcare and technology sales. The company utilizes a 'land and expand' strategy to build trust by addressing specific revenue cycle functions before expanding into additional solutions. This strategy has resulted in significant customer revenue expansion, with Net Revenue Retention (NRR) showing consistent year-on-year growth. The company targets mid-to-large health systems and large physician groups, and has dedicated teams for diverse specialties. The sales process involves a structured five-stage cycle, and the company competes in a fragmented RCM industry by offering a comprehensive platform and proprietary AI capabilities.

This section primarily details the various laws, regulations, and policies in India applicable to the company's business and operations, covering aspects related to information technology, data protection, telecommunications, and intellectual property. It outlines requirements from various statutes, including the Information Technology Act, the Digital Personal Data Protection Act, and rules concerning sensitive personal data. Furthermore, it discusses regulations related to foreign investment, foreign trade, and the protection of intellectual property rights.

The section details the extensive regulatory framework governing the company's operations, primarily focusing on various labour laws, tax regulations, and laws concerning the handling of personal and health information. It outlines numerous labour codes introduced by the Government of India to rationalize labour laws, including the Code on Wages, the Industrial Relations Code, and the Occupational Safety, Health and Working Conditions Code. Furthermore, it lists various tax laws applicable to the company, such as GST, Central Excise Act, and Income Tax Act, along with various state-wise tax laws. The text also covers laws related to e-waste management, arbitration, contract law, and various laws concerning anti-kickback statutes and physician self-referral laws related to healthcare services.

The company's history began with its incorporation as 'Adroit Global Solutions India Private Limited' in Chennai on November 12, 2010. The company underwent several name and conversion changes, including a name change to 'AGS Health Private Limited' in July 2011 and a conversion to a public limited company, changing the name to 'AGS Health Limited' in March 2026. The registered office has been changed on several occasions between 2011 and 2026. The company's Memorandum of Association has seen numerous amendments to its capital structure over the last decade, involving increases and reclassifications of equity shares. Key milestones include acquisitions and business transfers, such as acquiring a clinical documentation platform and acquiring business undertakings from an LLP.

The section details various transactions and structural changes, including agreements related to the acquisition of purchased business assets, the transfer of trademarks, and the acquisition of Fort Finance, Inc. by the company. It outlines a chain of transactions involving different entities and agreements effective around February and July 2023 and May 2025. Furthermore, it describes the current corporate structure, identifying a direct wholly-owned subsidiary and nine indirect subsidiaries, with no associates or joint ventures as of the date of the prospectus update.

The section details corporate information for three entities: AGS Health LLC, AGS Health Philippines, Inc., and ezDI, Inc. AGS Health LLC was formed through a conversion process on April 26, 2019, and holds interests in AGS Health LLC, which is held by AGS RCM Healthcare LLC. AGS Health Philippines, Inc. was incorporated on February 3, 2025, and its shareholding pattern shows AGS Health LLC as a shareholder. ezDI, Inc. was formed and had its name amended multiple times between 2014 and 2021. The text also outlines various agreements, including a Shareholders’ Agreement with BCP Asia II Topco VIII Pte. Ltd. and others, which govern rights and obligations related to the company's operation and securities.

The definitions section identifies the issuer as AGS Health Limited, a public limited company incorporated under the Companies Act, 1956. The registered and corporate office is located in Chennai, Tamil Nadu, India. The section also defines various terms related to the offer process, including different types of bidders, the role of Book Running Lead Managers, and various agreements and financial information formats.

This section details various terms related to the process of a public offering, including who can bid, the nature of the issue, and the parties involved in collecting bids. It specifies different bidder categories such as Retail Individual Bidders (RIBs), Eligible Employees, Qualified Institutional Bidders (QIBs), and Non-Institutional Bidders (NIBs). It also outlines procedures for bid collection, including designated locations and the role of various intermediaries and banks.

This section primarily defines various terms related to the offering process, investor types, and financial/operational metrics. It outlines agreements such as the Syndicate Agreement and Underwriting Agreement. It also details various technical and industry-specific terms, including those related to healthcare, AI, and financial reporting. Furthermore, it lists key performance indicators (KPIs) used by management to assess the company's financial performance, such as revenue growth, margins, and profitability.

This section primarily defines various financial and operational terms used in the prospectus. It includes definitions for various revenue metrics, workforce composition, employee attrition, and delivery sites. It also lists various abbreviations and legal/regulatory terms, such as those related to financial reporting standards (Ind AS, GAAP), various Acts, and regulatory bodies. Furthermore, it specifies conventions regarding the time period for financial data and highlights significant differences between Indian accounting standards (Ind AS), US GAAP, and IFRS.

The provided text discusses the use of audited consolidated financial statements for Fort Finance, Inc. in preparing Unaudited Proforma Financial Information, which is stated to be hypothetical and not indicative of actual financial conditions. It details rounding practices for figures and percentages, and clarifies that certain Non-GAAP financial measures are supplemental and not required by accounting standards. The text also covers currency conversions, industry data sourcing from the Zinnov Report, and various regulatory notices concerning offers of equity shares in different jurisdictions like the US, EEA, and UK.

This section discusses forward-looking statements within the Updated Draft Red Herring Prospectus – I, clarifying that such statements are based on current plans, estimates, and expectations and are subject to risks and uncertainties. It details various factors, such as regulatory changes, economic conditions, and market risks, that could cause actual results to differ materially from the projections made. The text cautions investors against placing undue reliance on these forward-looking statements as they are not a guarantee of future performance. Furthermore, it outlines obligations regarding the timely disclosure of material developments to bidders in India and the company regarding statements made in the Red Herring Prospectus.

This section details the structure of the offer, which is divided into Fresh Issue, Offer for Sale, and various reservation portions, including an Employee Reservation, QIB Portion, Non-Institutional Portion, and a Retail Portion. The Net Offer is further broken down into different categories, including portions reserved for various investor types like Anchor Investors and different types of Mutual Funds and Insurance Funds. The text also outlines procedures for allocation, including how under-subscription in certain portions can be met with spill-over from other categories, and specifies the relationship between the Offer and Net Offer as a percentage of the post-Offer paid-up equity share capital.

This section details the restated cash flows for the year ended March 31, 2026, showing various components such as operating activities, investing activities, and financing activities. It also presents unaudited proforma financial information, including a summary of the balance sheet and the profit and loss statement, alongside a summary of contingent liabilities as of March 31, 2026.

This section details the share capital structure of the company, including the authorized, issued, and paid-up share capital. It provides a comprehensive history of equity share allotments, including various issues, further issues, and employee stock option plans over several years. The text also mentions various resolutions and reclassifications of share capital, including a rights issue and a bonus issue, which affected the number and face value of the equity shares.

This section details various aspects of the company's capital structure, including equity allotment, share history, and shareholding patterns. It covers details of a preferential allotment, the issuance of equity shares for consideration, and the shareholding distribution as of the date of the Draft Red Herring Prospectus. The text also mentions various delays in filing statutory documents and the treatment of certain equity shares.

This section details the shareholding structure of major shareholders, including various snapshots of ownership as of different dates relative to the Draft Red Herring Prospectus. It provides information on the pre-offer, ten days prior, one year prior, and two years prior shareholding percentages for certain shareholders. Furthermore, it outlines the shareholding pattern of the Promoter group and additional top 10 shareholders, including post-offer shareholding details. The section also covers the history of equity share capital held by the Promoter, details regarding the build-up of promoter shareholding, and information on the average cost of acquisition of equity shares by the promoter selling shareholder.

The section details various aspects related to promoter shareholding, lock-in periods, and employee stock option schemes. It confirms that the promoter has consented to include a certain number of equity shares as the Minimum Promoters’ Contribution, constituting 20% of the fully diluted post-Offer Equity Share capital. Furthermore, it outlines restrictions on the sale, transfer, charge, or pledge of this contribution for a specified lock-in period. The text also specifies conditions regarding the acquisition of equity shares and the nature of the equity shares being offered.

The Offer involves a Fresh Issue of Equity Shares and an Offer for Sale by the Promoter Selling Shareholder. The net proceeds from the Fresh Issue are proposed to be utilized for funding various objects, primarily debt repayment and general corporate purposes. The utilization plan details the deployment of these net proceeds towards specific activities, including settling borrowings with subsidiaries and pursuing general corporate objectives.

The section details the various borrowings and the proposed utilization of net proceeds from the offer. It outlines that the net proceeds will first be used for the repayment or prepayment of specific loans incurred by the Identified Subsidiaries. Furthermore, the company proposes to repay or prepay borrowings from certain lenders, including those related to Jefferies Finance LLC, JCP BDC SPV I LLC, and SCI BDC SPV I LLC. The utilization of funds towards general corporate purposes is subject to a limit of 25% of the gross proceeds, and the allocation of funds will be determined by the Board based on business requirements.

This section details the estimated expenses related to the Offer for Sale, which are broken down into various categories. The estimated offer expenses include fees and commissions for various parties involved in the offer process, such as underwriting, brokerage, and regulatory filings. The text specifies different components of these expenses based on the portion of the offer size allocated to different bidder categories, including RIBs, Non-Institutional Bidders, and Eligible Employees. Furthermore, it outlines processing fees and selling commissions based on the type of bidder and the mechanism used for the application submission.

This section primarily compares the company's Key Performance Indicators (KPIs) against those of its listed industry peers. It details various financial and operational metrics, including revenue, profitability, and customer base metrics, for the fiscal years 2026, 2025, and 2024. The KPIs are intended to help investors assess the company's performance relative to its competitors.

This section primarily contains financial performance indicators and details regarding the offer-for-sale process, including various metrics for the issuer and its peers. It provides comparative data for profit/loss, margins, net debt, and customer metrics across different fiscal years. Furthermore, it includes details on the pricing of equity shares, such as the weighted average cost of acquisition (WACA), floor price, and cap price, which are used to justify the offer price.

The provided text details special tax benefits available to the company and its shareholders under various Direct Tax Laws, including provisions related to corporate tax rates, deductions, and dividend treatment. It also outlines special tax benefits under Indirect Tax Laws, primarily concerning GST, including export-related benefits. Furthermore, a statement is provided regarding possible special tax benefits for a material subsidiary company under the tax laws.

This section details the statement of possible special tax benefits available to AGS RCM Healthcare LLC, a material subsidiary of AGS Health Limited, under Indian tax laws. It clarifies that the subsidiary is considered a non-resident for tax law purposes, and the tax rates and taxation are subject to benefits under Double Taxation Avoidance Agreements between India and the subsidiary's fiscal domicile country. The statement also notes that the subsidiary is not eligible for any general tax benefits under the applicable laws.

This section primarily deals with statements regarding possible special tax benefits available to various subsidiaries of AGS Health Limited under Indian tax laws. The statements confirm that the benefits are contingent upon the subsidiary company and its shareholders fulfilling prescribed conditions based on future business imperatives. Furthermore, the documents clarify that the discussed benefits do not encompass general tax benefits and that the views expressed are not exhaustive. Investors are advised to consult their own tax consultants due to the individual nature of tax consequences and changing laws.

The provided text primarily deals with statements regarding possible special tax benefits available to subsidiaries under Indian tax laws. It outlines that the subsidiary company is considered a non-resident for tax law purposes, and the tax rates and taxation are subject to benefits under Double Taxation Avoidance Agreements depending on the non-resident's fiscal domicile and fulfillment of other conditions. Furthermore, the statement clarifies that the benefits discussed are only a summary and do not constitute a complete analysis of all existing and potential tax consequences. It is advised that investors consult their own tax consultants regarding specific tax implications arising from their participation in the proposed Initial Public Offering.

This section discusses special tax benefits available to the Consolidated US Group under US tax laws, primarily focusing on the treatment of income from a controlled foreign corporation (CFC). It details that the Consolidated US Group includes the CFC's GILTI in its gross income, which is subject to a 21% U.S. Federal Corporate Income Tax Rate, with a potential 50% deduction allowed under Code Section 250. Furthermore, it states that the Consolidated US Group, including its subsidiaries, is not eligible for certain tax benefits under applicable US tax laws.

This section discusses various reporting and withholding requirements related to payments and dispositions of Equity Shares involving U.S. Holders. It covers issues such as filing IRS Form 8621 for U.S. Holders owning Equity Shares during years the Company is a PFIC. Furthermore, it details rules concerning information reporting and backup withholding on payments made to U.S. Holders. Finally, it outlines reporting obligations for U.S. Holders who own specified foreign financial assets.

This section details the formal examination and reporting process for the financial statements of AGS Health Limited. It outlines that the Restated Summary Statements were examined by Chartered Accountants and prepared based on audited financial statements. The report confirms that the statements were prepared retrospectively to reflect changes in accounting policies and errors. The auditors provided assurance regarding the compliance of the statements with relevant laws and regulations.

This section presents the restated summary statements for AGS Health Limited, including the statement of assets and liabilities, profit and loss, and changes in equity, for the fiscal years ending March 31, 2026, March 31, 2025, and March 31, 2024. The financial statements detail various liabilities, revenues, expenses, and resulting profits, along with the movement in equity components. The data is provided in Rupees millions, with specific notes regarding accounting policies and restatement adjustments.

This section details various restatement adjustments and commentary related to the financial statements for AGS Health Limited across different reporting periods. It includes information on profit, reserves, and various adjustments made to the financial figures. Furthermore, the section addresses auditor comments regarding statutory dues, the relationship with other entities, and limitations concerning the audit trail functionality of the accounting software used by the company.

This section details various aspects of the financial statements, including corporate information, accounting policies, and consolidation procedures. It outlines the relationship between the Holding Company and its subsidiaries, the basis for preparing consolidated and standalone financial statements, and the treatment of different asset classes and liabilities. The policies cover aspects such as the functional currency, current versus non-current classification, the operating cycle, and the depreciation and amortization policies for property, plant and equipment and intangible assets.

This section details various accounting policies related to the recognition and measurement of different financial statement line items, including impairment testing for assets, lease accounting, provisions, contingent liabilities, and revenue recognition for contracts with customers. It outlines specific rules for handling contracts, including how revenue is measured, the treatment of various income types, and the accounting for various liabilities and assets. Furthermore, it covers policies for dealing with income taxes, deferred tax, and employee benefits like gratuity and compensated absences.

This section details various accounting policies related to financial statements, including the recognition and measurement of deferred tax, derivatives, financial assets, and liabilities. It outlines specific rules for handling temporary differences, hedging relationships, and the classification of debt instruments based on contractual cash flow characteristics and business models. The policies cover aspects such as how cash flows are reported, how business combinations are accounted for, and the subsequent measurement of financial instruments.

This section details the accounting policies related to financial liabilities, including fair value measurement, the use of estimates and judgments, and exceptional items. It outlines how financial instruments are measured, how assets and liabilities are categorized based on a fair value hierarchy (Level 1, 2, or 3), and various accounting treatments for share-based payment awards. Furthermore, it discusses the impact of recent accounting pronouncements and amendments to Indian Accounting Standards.

This section details the movement in right-of-use assets and lease liabilities, showing balances as of March 31, 2026, March 31, 2025, and March 31, 2024, for both consolidated and standalone figures. It also presents the recognition of expenses in the statement of profit and loss, including depreciation expense, interest expense on lease liabilities, and a gain on the termination of a lease. Furthermore, the text discusses the nature of lease contracts, including the restrictions on assigning and subleasing assets and the use of short-term lease recognition exemptions.

This section details various financial statement components, including intangible assets, financial assets, trade receivables, cash, and cash equivalents for AGS Health Limited across three fiscal years ending March 31, 2024, 2025, and 2026. Key figures are presented for assets like intangible assets under development, security deposits, trade receivables, and cash balances, with some movement details provided for intangible assets and cash flows.

This section details various components of the financial statements, including deferred tax assets and liabilities, and the balance sheet structure. It shows movements in deferred tax items, reconciliation of effective tax rates, and the statement of profit and loss including Other Comprehensive Income (OCI). Furthermore, it provides information on the equity share capital structure, including authorized, issued, and subscribed shares, along with details on share conversions and bonus/rights issues undertaken during the year.

This section details various aspects of the company's financial statements, including shareholding structure, equity movements, and various liabilities and borrowings. It covers details on the change in ownership of shares, movements in various equity accounts like securities premium and cash flow hedge reserves, changes in retained earnings, and the structure of borrowings. Furthermore, it lists details on trade payables, provisions, and other financial liabilities.

This section details various financial statement components for AGS Health Limited across three fiscal years, including revenue, other income, employee benefits, finance costs, depreciation, other expenses, and other non-operating items. Revenue from contract with customers showed a consistent trend, with the most recent year (ending March 31, 2026) being the highest. The data also includes details on trade receivables, deferred revenue, and customer concentration. Furthermore, the section provides breakdowns of various expenses, such as salaries, staff welfare, and various operational costs, alongside details on interest, depreciation, and miscellaneous expenses.

This section details various accounting judgements, estimates, and assumptions made by the company, covering areas such as tax recognition, employee benefits, useful lives for Property, Plant and Equipment, and the fair value estimation for share-based payment transactions. It also outlines financial risk management policies, including sensitivity analysis for interest rate and foreign currency risks, and details regarding credit risk management for trade receivables. Furthermore, the notes provide information on the liquidity risk associated with financial liabilities and the framework for capital management, including the objective of maximizing shareholder value through debt and equity balance optimization.

This section details the fair value hierarchy for the Group's assets and liabilities as of different dates, including various financial instruments. It specifies the valuation techniques used for different items, such as discounted cash flow for borrowings and option pricing models for cash-settled share-based payment liabilities. Furthermore, it provides information on revenue from customers, non-current assets, and details regarding CSR activities and the treatment of micro, small, and medium enterprises (MSME) transactions. Finally, it outlines the details of foreign currency forward contracts used for hedging purposes.

This section details various notes related to the financial statements, including hedging instruments, related party disclosures, and transactions. It presents data comparing financial positions across different reporting dates and categorizes transactions with related parties. Specific details are provided on the nature of transactions, such as the sale of services and trade receivables, and information regarding employee benefit expenses like gratuity plans.

This section details various financial and actuarial statements for AGS Health Limited across three fiscal years, including March 31, 2026, March 31, 2025, and March 31, 2024. It presents data on current service costs, interest costs, recognized expenses, and components of other comprehensive income. Furthermore, it includes a reconciliation of the present value of defined benefit obligations and fair value of plan assets, along with sensitivity analyses for key actuarial assumptions such as discount rates, salary increases, and attrition rates. The data also covers details on capital commitments, contingent liabilities, and various share-based payment arrangements.

This section details various notes related to the financial statements, including share-based compensation plans, transfer pricing policies, and business combinations. It outlines the details of an employee stock incentive plan, including the number of shares available for grant and the vesting conditions. Furthermore, it describes the acquisition of Fort Finance Inc., detailing the consideration paid and the accounting treatment for the acquired business's assets and liabilities, including the resulting goodwill.

This section primarily details the presentation of financial statements, including various components of the Profit and Loss, Balance Sheet, and Cash Flow, across different reporting periods. It includes segregated data for various entities like Fort Topco Inc, AGS RCM Holdco LLC, AGS RCM Intermediate Co LLC, AGS RCM Healthcare LLC, and AGS Health LLC. The text also covers exceptional items such as the statutory impact of new Labour Codes and transaction bonus expenses, along with details regarding share-based payments and compliance with various legal and financial regulations.

This section presents the unaudited proforma Statement of Profit and Loss for AGS Health Limited for the year ended March 31, 2026, showing adjustments resulting from the acquisition of Fort Finance Inc. The data includes comparisons between the consolidated statement and the historical statement of the acquired entity, along with various adjustments and the resulting profit/loss figures. The statement details revenue, income, expenses, tax components, and the final profit/loss for the period, including items that will and will not be reclassified to the profit and loss statement.

This section presents the unaudited Proforma Statement of Profit and Loss for AGS Health Limited for the year ended March 31, 2026, comparing it with historical data from Fort Finance Inc. The profit calculation involves various adjustments, including intragroup elimination and acquisition adjustments. The statement details the components of income, expenses, and tax, culminating in the net profit for the period. It also provides basic and diluted earnings per equity share.

This section presents the unaudited proforma Balance Sheet and Profit and Loss statements for AGS Health Limited as of March 31, 2024, including historical data from Fort Finance Inc. The Balance Sheet details assets and liabilities, while the Profit and Loss statement shows the performance for the year ended March 31, 2024. The notes clarify the basis of preparation, including the impact of an acquisition of Fort Finance Inc. and the subsequent change in the subsidiary relationship.

This section details the methodology and adjustments used to prepare Unaudited Proforma Financial Information, primarily to illustrate the impact of an acquisition. The information is derived from restated summary statements and audited financial statements of the acquired enterprise, incorporating purchase price allocation and intragroup elimination adjustments. Exchange rates used for translation into Indian Rupees are provided for different reporting periods.

This section details various adjustments made to financial figures, including transactions affecting finance costs, depreciation, and deferred tax charges, across three fiscal years ending March 31, 2026, March 31, 2025, and March 31, 2024. It also outlines intragroup elimination adjustments related to revenue, expenses, and balances between the company and the acquired enterprise. Finally, the document presents the calculation methodology for Earnings Per Share (EPS) for the same periods, detailing the impact of share conversions and bonus issues on the weighted average number of equity shares.

The independent auditor's report confirms that the Interim Consolidated Financial Statements of Fort Finance Inc. and its subsidiaries present a true and fair view in conformity with Indian Accounting Standard 34 (Ind AS 34). The report covers the financial position, performance, cash flows, and changes in equity for the period from April 1, 2025, to July 31, 2025. The report also details the responsibilities of the Board of Directors and the auditors regarding the financial statements and internal controls.

This section details the consolidated financial performance of Fort Finance Inc. for the four-month period ended July 31, 2025, comparing it to the same period in 2024. The Profit & Loss statement shows a loss before tax of Rs. 4,623.46 in the current period, compared to Rs. 77.11 in the prior year. Key expenses include employee benefits and finance costs, which showed significant changes. The cash flow statement provides insights into the cash generated from operating, investing, and financing activities during this period.

This section presents the consolidated statement of cash flows for the four-month period ended July 31, 2025, showing a net increase in cash and cash equivalents of ₹519.79 Crore, compared to ₹10.45 Crore in the same period of the previous year. The statement details the components of cash and cash equivalents, including balances with banks and the net foreign exchange difference. The document also outlines various accounting policies, including the basis of preparation under Indian Accounting Standards (Ind AS), the treatment of financial assets and liabilities, and criteria for classifying assets and liabilities as current or non-current.

This section details various accounting treatments related to intangible assets, impairment testing, leases, provisions, contingent liabilities, and revenue recognition from contracts with customers. It outlines the criteria for recognizing and measuring these items, including rules for capitalization, amortization, impairment assessments, and the treatment of various contractual arrangements.

This section details various accounting treatments for financial instruments, income recognition, and tax provisions within the financial statements. It outlines specific rules for recognizing contract liabilities, interest income, export incentives, and income taxes, including the treatment of current and deferred taxes. Furthermore, the text describes the measurement and classification of financial assets, including debt instruments, based on business models and contractual cash flow characteristics, and the subsequent measurement of these assets for subsequent reporting periods.

This section primarily discusses the accounting treatment and measurement of financial liabilities, including initial recognition, subsequent measurement methods like amortized cost, and derecognition procedures. It details how various financial instruments are classified based on their purpose, such as trading or hedging, and the recognition of fair value changes in the statement of profit and loss. Furthermore, the text covers fair value measurement principles, the hierarchy of assets and liabilities, and accounting for share-based payments. It also addresses the use of management estimates and judgments, as well as recent accounting pronouncements regarding liability classification and events occurring after the reporting period.

This section details the movement in right-of-use assets and lease liabilities over a four-month period ending July 31, 2025, as well as various financial statement line items. The movement in right-of-use assets showed additions of Rs. 174.40 and depreciation expenses of Rs. 13.42, while lease liability movements included interest accretion and payments. Furthermore, the text discusses the nature of lease contracts, including those with extension and termination options, and details the impairment testing performed on goodwill and other intangible assets.

This section details various financial statement line items for Fort Finance Inc. for the four-month period ended July 31, 2025, comparing it to March 31, 2025. It includes breakdowns of trade receivables, cash and cash equivalents, financing activities, and other current assets. The data shows movements in liabilities, interest, and foreign exchange differences across different reporting dates.

This section details various financial statement line items for Fort Finance Inc. for the four-month periods ended July 31, 2025, and July 31, 2024. Key information includes details on borrowings, trade payables, revenue from operations, finance costs, depreciation, and other expenses. It also provides information on earning per share calculations, including basic and diluted EPS.

This section details various accounting judgements, estimates, and assumptions related to the financial statements, covering aspects such as financial risk management, market risk, interest rate risk, foreign currency risk, and credit risk. It outlines management's responsibilities in making judgements that affect reported amounts, including those related to leases, impairment tests, and deferred tax assets. Furthermore, it provides details on liquidity risk management, the concentration of credit risk in trade receivables, and the fair value hierarchy for assets and liabilities. The text also includes disclosures on related party transactions and capital commitments.

This section details various share-based payment arrangements and exceptional items recognized in the consolidated financial statements for the period ended July 31, 2025. It covers the status of rollover units, phantom interest arrangements, and the cancellation of outstanding options. Furthermore, it discloses employee benefits expenses, including share-based payments, a transaction bonus related to a group acquisition, and costs incurred for potential divestment activities.

The Independent Auditor's Report confirms that the Consolidated Financial Statements of Fort Finance Inc. and its subsidiaries present a true and fair view of the Group's financial position as of March 31, 2025, in conformity with Indian Accounting Standards. The report details the audit procedures performed and outlines the responsibilities of the Board of Directors and management regarding the financial statements and internal controls. The report also specifies that the financial statements were prepared for inclusion in various prospectuses.

This section details the consolidated financial performance of Fort Finance Inc. for the years ended March 31, 2025, and March 31, 2024, covering the Profit & Loss statement, changes in equity, and cash flows. The Profit & Loss statement shows a decrease in profit before tax and exceptional items, with losses reported for the year. The statement of changes in equity shows movements in equity share capital and other equity components. Finally, the cash flow statement provides details on cash generated from operating, investing, and financing activities.

This section details the consolidated cash flows for Fort Finance Inc for the year ended March 31, 2025, showing a net increase in cash and cash equivalents. It also outlines the accounting policies, including the basis of preparation in accordance with Indian Accounting Standards (Ind AS) and the treatment of various assets and liabilities. The policies specify that financial statements are prepared on a historical cost basis, with certain assets and liabilities measured at fair value or revalued amounts. Furthermore, the group has elected to continue with the carrying value of property, plant, and equipment under the previous GAAP during the transition to Ind AS.

This section details various accounting treatments related to intangible assets, leases, provisions, contingent liabilities, and revenue recognition. It outlines policies for capitalization, amortization, impairment testing, and recognition criteria for different types of contracts and liabilities. Specific guidance is provided on how to handle development expenditures, impairment losses, lease accounting (including Right-of-Use assets and lease liabilities), and the recognition of provisions and contingent items.

This section details various accounting treatments for different financial items, including contract acquisition costs, interest income, income taxes, cash and cash equivalents, earnings per share calculations, business combinations, and financial instruments. It outlines specific methodologies for recognizing income, handling tax timing differences, defining cash equivalents, calculating EPS, and classifying and measuring financial assets and liabilities based on their contractual cash flow characteristics and the business model.

This section primarily discusses the accounting treatment for financial liabilities, including initial recognition, subsequent measurement methods like amortized cost, and rules for financial liabilities classified as held for trading or designated at fair value through profit or loss. It details how interest-bearing loans and borrowings are measured using the Effective Interest Rate (EIR) method, and outlines the process for derecognition. The text also covers fair value measurement principles, including the definition of fair value, the hierarchy of fair value inputs (Level 1, 2, and 3), and accounting for share-based payments. Finally, it addresses recent accounting pronouncements, such as amendments to Ind AS 1 regarding liability classification and rules for events occurring after the reporting period.

This section details the movement in right-of-use assets and lease liabilities, including depreciation expense and interest expense on lease liabilities. It also presents various financial asset and intangible asset balances, including goodwill and computer software, across different reporting periods. Furthermore, it provides details on trade receivables, including their ageing schedule and the recognition of expected credit losses.

This section details various components of Fort Finance Inc.'s financial statements, including trade receivables, cash balances, financing activities, and equity details. It presents comparative data for trade receivables, cash and cash equivalents, changes in liabilities, and various tax and deferred tax items. Furthermore, it shows the movement in equity components like retained earnings and employee stock option reserves, alongside the outstanding term loans.

This section details various financial statement line items and related data for Fort Finance Inc. as of March 31, 2025, compared to March 31, 2024. Key data includes net financial figures, trade payables, revenue recognition, finance costs, depreciation, and various operating expenses. The text also mentions financial covenants related to borrowings and details regarding trade payable aging and the calculation of Earnings Per Share (EPS).

This section details various accounting judgements, estimates, and assumptions related to the financial statements, covering areas such as financial risk management, market risk, and interest rate risk. It discusses the management's role in making judgements affecting reported amounts, including those related to leases, impairment tests, and deferred tax assets. Furthermore, it outlines the Group's exposure to different financial risks and details liquidity risk management through monitoring contractual maturities of financial liabilities. The text also provides comparisons of financial liabilities and various financial instruments across reporting periods.

This section details various share-based payment arrangements, including rollover units, phantom interest, and senior leadership phantom arrangements, as of the reporting dates. It also discusses the cancellation of such options and the classification of related share-based payments as exceptional items in the consolidated financial statements. The data provided includes figures for these arrangements for the years ended March 31, 2025, and March 31, 2024.

The provided text contains the Independent Auditor's Report concerning the consolidated financial statements of Fort Finance Inc. for the year ended March 31, 2024. The report confirms that the financial statements present a true and fair view in conformity with Indian Accounting Standards (Ind-AS). It outlines the responsibilities of the Board of Directors and management regarding the financial statements, including the assessment of the group's ability to continue as a going concern. The text also includes the consolidated Balance Sheet as of March 31, 2024, showing key components of assets, liabilities, and equity.

This section details the consolidated financial performance of Fort Finance Inc. for the year ended March 31, 2024, presenting key profit and loss figures, changes in equity, and cash flows. The Profit and Loss statement shows a loss before tax of ₹95.55 Crore for the year, while the Cash Flow statement indicates net cash from operating activities of ₹192.37 Crore.

This section details the consolidated statement of cash flow for Fort Finance Inc. for the year ended March 31, 2024, showing changes in cash and cash equivalents, including net foreign exchange differences. It also outlines the material accounting policies, including the basis of preparation in accordance with Indian Accounting Standards (Ind AS) and the treatment of various assets and liabilities. The policies cover consolidation procedures, the classification of current versus non-current items, and the depreciation methods for property, plant, and equipment.

This section details various accounting treatments related to intangible assets, leases, provisions, contingent liabilities, and revenue recognition. It outlines policies for capitalization, amortization, and impairment testing for different asset classes. Specific attention is given to how revenue is recognized from contracts with customers, including considerations for variable consideration and unbilled revenue, as well as definitions for trade receivables, contract assets, and contract liabilities.

This section details various accounting treatments related to financial reporting, including contract acquisition costs, income recognition, tax provisions, cash management, earnings per share calculation, business combinations, and financial instruments. It outlines specific methodologies for recognizing interest income, handling income taxes (current and deferred), managing cash flows, calculating EPS, and accounting for business combinations and goodwill. Furthermore, it provides extensive guidance on the classification and subsequent measurement of financial assets and liabilities according to various accounting standards, including amortized cost, fair value through profit or loss, and fair value through other comprehensive income.

The provided text primarily discusses the accounting treatments for financial liabilities, including initial recognition, subsequent measurement methods like amortized cost, and criteria for classifying liabilities as held for trading or designated as fair value through profit or loss. It details how interest-bearing loans and borrowings are measured using the Effective Interest Rate (EIR) method, and the process for derecognition. The text also covers fair value measurement principles, including market accessibility and the hierarchy of inputs used for valuation. Furthermore, it addresses accounting for share-based payments and recent accounting pronouncements related to liability classification and loan agreements.

This section details the movement and balances of various assets and liabilities as of March 31, 2024, covering capital work-in-progress, right-of-use assets, lease liabilities, goodwill, and intangible assets. The data shows changes in these balances over the period, including additions, deletions, depreciation, interest expense, and various exchange differences. Furthermore, it outlines the methodology used for goodwill impairment testing, including assumptions on revenue growth rates and discount rates for value in use calculations.

This section details various financial statement line items as of March 31, 2024, including financial assets, cash balances, current and non-current assets, tax provisions, and equity share capital. Key movements in trade receivables, cash flows, and deferred tax balances are presented for comparison with the previous year.

This section details various financial statement components for Fort Finance Inc. as of March 31, 2024, compared to March 31, 2023. Key information includes movements in retained earnings, foreign currency translation reserves, borrowings, trade payables, revenue recognition, other income, employee benefits, finance costs, and depreciation/amortisation expenses. The data provides figures for both the current year and the previous year across these line items.

This section details various financial statement line items, including operating expenses, components of other comprehensive income, earnings per share, and significant accounting judgements. It presents changes in various expenses and income components between the fiscal years ending March 31, 2024, and March 31, 2023. Furthermore, it outlines risk management policies concerning financial instruments, including market risk, interest rate risk, credit risk, and liquidity risk. The text also covers aspects of capital management, including meeting financial covenants and maximizing shareholder value.

This section provides detailed financial disclosures for Fort Finance Inc. as of March 31, 2024, covering fair value measurements, related party transactions, and share-based payment details. It includes comparisons of financial liabilities, various asset and liability fair values, and information regarding transactions with related parties such as AGS Health Private Limited. Furthermore, it outlines details on share-based payments, including phantom interest arrangements, and provides a breakdown of the ownership and performance of the Group's subsidiaries.

This section provides detailed financial statement notes for Fort Finance Inc., covering various financial metrics as of March 31, 2024, and for the year ended March 31, 2024. It includes comparisons across different reporting periods and details for calculating key ratios such as earnings per share, return on net worth, EBITDA, and net debt. The data includes reconciliations for profit, EBITDA, and net worth, along with definitions for non-GAAP financial measures.

This section details various profit and loss reconciliations, return metrics, and EBITDA calculations for the financial years ended March 31, 2026, 2025, and 2024, including both consolidated and standalone figures. It also presents proforma profit and EBITDA figures, along with various reconciliation points for net worth and debt, and discusses the company's market position and business model.

This section details various aspects of the company's operations, customer relationships, and financial performance metrics, including retention rates and revenue generation from customers. It highlights the company's global delivery footprint, the dependency on direct relationships with healthcare providers, and the methodology used to measure customer retention and revenue retention. Furthermore, it discusses the nature of their technology portfolio, the growth projections for the technology spend market, and the strategy for organic and inorganic growth through acquisitions.

This section details various accounting policies related to impairment, leases, provisions, contingent liabilities, revenue recognition, and tax accounting for the company. It outlines specific criteria for determining asset impairment, the treatment of different lease types, the recognition of provisions for obligations, and the accounting for various tax items such as current and deferred tax.

This section details the accounting policies for financial statements, including the treatment of deferred tax assets and liabilities, business combinations, share-based payments, and the components of income and expenditure. It outlines how revenue, other income, and various expenses are classified, and then presents a comparison of the results of operations for Fiscal Years 2026, 2025, and 2024, highlighting the impact of an acquisition on the consolidated results.

This section details various financial performance metrics and cash flow movements for the company across different fiscal years, including comparisons on a proforma basis. Key changes are noted in employee benefits, finance costs, depreciation, and other expenses, alongside significant shifts in profitability and tax provisions. The data also includes liquidity and capital resource information, such as borrowings and cash balances.

This section details various financial metrics, cash flows, and liabilities for fiscal years 2024, 2025, and 2026. It provides breakdowns of profit before tax, working capital changes, cash flows from operating, investing, and financing activities, as well as information on indebtedness and contingent liabilities. The text also covers aspects of market risk, credit risk, liquidity risk, and dependencies on customers.

This section details the capitalization and financial indebtedness of the company as of March 31, 2026, derived from restated financial information. It presents figures for borrowings, equity, and various ratios, along with extensive details regarding the terms and conditions of the credit facilities availed by the company and its subsidiaries. The text outlines various provisions concerning interest rates, tenure, security requirements, prepayment provisions, and events of default related to the borrowings.

This section outlines several risks associated with the investment, including the potential for unforeseen events to negatively impact the company's business, financial condition, and cash flows. It details challenges related to managing the consolidated business operations following an acquisition, which may create new structural and administrative difficulties, especially in an internationally dispersed context. Furthermore, the section discusses the limitations of the provided financial information, noting that proforma figures are illustrative and not indicative of future results. Significant risks are also highlighted concerning compliance with U.S. healthcare laws and regulations, which could lead to penalties or operational changes. Finally, the section addresses dependencies on existing customer relationships and the potential for contract terminations or disputes that could affect revenue and profitability.

The company faces risks related to customer concentration, as a significant portion of its revenue depends on a limited number of key customers. The company is exposed to industry consolidation trends in the U.S. healthcare sector, which could lead to changes in customer relationships or pricing pressure. Furthermore, the business is subject to various regulatory and economic risks associated with operating in the U.S. market, including potential changes in healthcare legislation and reimbursement policies. There are also significant cybersecurity risks concerning the handling of sensitive patient data, and risks related to the impairment of acquired goodwill.

The company faces risks related to the development and introduction of new solutions, including AI/ML, which could negatively impact operations and cash flows if new solutions are not successfully developed or introduced to meet customer demands. There is a concern that new features might not sufficiently differentiate the company from competitors. Furthermore, the rapid advancement of AI technologies poses a challenge as it may fundamentally alter the demand for services. The business model relies heavily on skilled human resources, making it vulnerable to talent poaching and increased recruitment/training costs. The company also faces potential litigation risks and implementation challenges related to integrating solutions with diverse Electronic Health Record (EHR) systems, which could lead to customer loss or increased costs.

The risk factors outlined in this section cover several critical areas impacting the company's operations and financial stability. Risks include potential technical obstacles in product development, which could lead to software errors, and the resulting liability claims from customers. There is also a risk associated with the use of open-source software, which could lead to legal challenges regarding licensing compliance. Furthermore, the company faces negative cash flows and potential cash flow issues in the future. Debt financing poses risks related to the ability to meet payments, refinance debt, or face default, including the possibility of asset foreclosure. Collection risks are highlighted due to potential delays in receiving payments from customers. Finally, there is a risk of customer churn and the potential for disruptions due to reliance on third-party vendors.

The company faces risks related to the length and unpredictability of its sales cycle, which can cause fluctuations in operating results and cash flows. There is a significant risk concerning the handling of personal health information, which could lead to fines, liabilities, and legal proceedings due to evolving data privacy regulations. Furthermore, the company is exposed to risks from foreign currency exchange rate fluctuations impacting consolidated financial statements, as well as risks associated with reliance on third-party infrastructure and potential disruptions. There are also concerns regarding delays in statutory filings and the possibility of future regulatory actions, as well as risks stemming from related party transactions and the potential for conflicts of interest.

The company disclosed details regarding statutory dues paid to employees across various fiscal years, including Provident Fund, Employee State Insurance, Professional Taxes, and Income Tax. There are noted delays in the payment of some statutory dues, which were attributed to technical glitches, though the company has implemented internal procedures to prevent future delays. Furthermore, the company faces risks related to the potential for future delays or defaults in statutory compliance, which could lead to regulatory action and penalties. The company is also subject to restrictions on investing in foreign subsidiaries under Indian overseas investment laws, which may constrain its ability to acquire stakes in overseas entities. Additionally, the company's audit reports contain modifications, and there is a lack of assurance regarding future audit reports. There are also risks associated with contractual indemnification obligations, potential claims from customers regarding data usage, and exposure to legal liabilities from various sources. Finally, the company is subject to laws related to economic sanctions and anti-bribery laws, and there are concerns about potential violations of these laws by employees or agents.

The risk factors outlined in this section cover several areas, including issues related to promoter control, differences in accounting standards, potential fraud and misconduct by employees, risks associated with intellectual property, dependency on third-party technology, and risks related to insurance coverage. There are also concerns about the accuracy of provided information, the potential for litigation, and the risks associated with the licensing of third-party intellectual property. Furthermore, the section addresses risks concerning the reliability of operational metrics, the potential for issues with leased premises, and the uncertainty surrounding future financing and the issuance of equity shares.

The company relies on management estimates and prevailing market conditions for the utilization of net proceeds, which are subject to change, and prospective investors must rely on management's judgment. There are risks related to potential conflicts of interest among promoters, directors, and management, which could impact business decisions. The company faces various operational and regulatory risks, including potential non-compliance with evolving laws, anti-corruption laws, and data protection regulations. Furthermore, the business is exposed to macroeconomic risks, political instability, and volatility in global markets, which can affect access to capital and overall performance.

The risk factors discussed cover several areas, including various tax implications related to capital gains and dividends, uncertainty surrounding Indian tax laws, and potential impacts from inflation on operating margins. There are also risks associated with market surveillance measures imposed by SEBI, potential restrictions on takeovers, and issues related to the listing and trading of equity shares. Furthermore, risks exist concerning the ability of investors to sell shares, the potential for dilution from future equity issuances, and difficulties in enforcing foreign judgments. Finally, there are concerns about the volatility of exchange rates and the uncertainty surrounding the classification of the company for U.S. federal income tax purposes.

The company discusses potential tax implications related to its Passive Foreign Investment Company (PFIC) status and the rules governing United States persons owning significant stakes in the company's stock. It explains that if a United States person owns at least 10% of the stock, they may face adverse U.S. federal income tax consequences. Furthermore, the text details that the company is expected to be reported as a Controlled Foreign Corporation (CFC) by affiliates of Blackstone who own equity in the Promoter Selling Shareholder. This status could require United States shareholders to report and include a portion of the company's income in their U.S. taxable income, and it may restrict certain tax deductions or foreign tax credits for such shareholders. The company cannot guarantee assistance in determining this status or providing necessary information to comply with reporting and tax obligations.

The section states that there are no outstanding criminal proceedings, regulatory actions, or claims related to direct and indirect taxes involving the Company, its Subsidiaries, Promoters, Directors, Key Managerial Personnel, or Senior Management Personnel. It further confirms no disciplinary actions by SEBI or stock exchanges against the Promoter in the last five financial years. The text details criteria for identifying material civil litigation, including thresholds based on the company's net worth, turnover, and profit or loss. It also discloses several pending civil litigation matters involving the Company, its Subsidiaries, and Directors, as well as various criminal proceedings against Directors.

The section details several aspects of litigation, tax matters, and regulatory approvals. There is a noted proceeding involving the Company Secretary and Compliance Officer concerning alleged misclassification of exported services and potential penalties under the Customs Act. Regarding tax claims, there are pending proceedings related to a subsidiary's non-filing of income tax returns, which involves a dispute over the treatment of alleged income. Furthermore, the text outlines various approvals obtained by the company and its subsidiaries, including corporate incorporation certificates, tax registration numbers, and various professional and trade licenses. Finally, it mentions pending trademark applications and issues related to intellectual property.

The section details the criteria for identifying group companies under the SEBI ICDR Regulations. It outlines two main methods: first, considering companies with which related party transactions occurred, and second, considering other companies deemed material by the Board based on a Materiality Policy. Companies involved in related party transactions are considered group companies if they transact under Indian Accounting Standard (Ind AS) 24. For the materiality policy, companies are considered group companies if they are part of the Promoter Group or have entered into transactions with the Company exceeding 10.00% of the total consolidated revenue from operations during the most recent completed financial year or period disclosed.

The section details various authorizations and confirmations related to the offer process, including resolutions passed by the Board and Shareholders for the offer and the Draft Red Herring Prospectus. It also confirms the eligibility of the offered shares under specific SEBI ICDR Regulations and outlines various compliance confirmations regarding prohibitions by regulatory authorities. Furthermore, the text specifies conditions for eligibility under SEBI ICDR Regulations, including requirements for net tangible assets and monetary assets. It also covers agreements for the dematerialization of equity shares and various disclaimers regarding the offering and jurisdiction.

The section details various representations and acknowledgments related to the sale and transfer of Equity Shares, particularly concerning transactions outside the United States. It outlines specific legends that Equity Shares must bear, restricting their offer or sale within the US unless certain exemptions apply. Furthermore, it specifies conditions under which purchasers are deemed to have acknowledged the prospectus content, including restrictions on the nature of the transaction (e.g., offshore transactions). The text also includes disclaimers from BSE and NSE regarding the scrutiny of the Draft Red Herring Prospectus by the respective exchanges.

This section details the historical price information for issues handled by ICICI Securities Limited, Jefferies India Private Limited, and J.P. Morgan India Private Limited. It provides various metrics such as the number of IPOs, total funds raised, and performance of these issues over different timeframes (30th, 90th, and 180th calendar days from listing). The data is sourced from NSE and BSE, and notes clarify the methodology used for calculating these performance metrics and the discounts offered to eligible employees.

The section details various aspects related to the handling of investor grievances and the process for resolving issues arising from the offer, including procedures under the SEBI ICDR Master Circular. It outlines the retention of records with the Registrar to the Offer for at least eight years from the listing date. Furthermore, it specifies procedures for addressing grievances related to bids made through the UPI Mechanism, including compensation mechanisms for delays in fund unblocking or non-allotment scenarios. The company states that it has not received investor grievances in the last three financial years prior to the filing of the Updated Draft Red Herring Prospectus - I.

The section outlines various regulatory requirements and conditions governing the offer of equity shares, stipulating that the shares are subject to several laws and regulations including the Companies Act, SEBI ICDR Regulations, SCRA, SCRR, and various guidelines from SEBI, the Government of India, Stock Exchanges, RBI, and RoC. It details the rights of equity shareholders, the process for payment of dividends, and the procedures for allotment, including the use of dematerialized forms and agreements with Depositories and Registrars. Furthermore, it specifies different timelines and submission windows for various bidder categories, including restrictions related to UPI mandates and the handling of bid revisions.

This section details various procedural aspects related to the bid and allotment process, including time limits, bid processing rules, and handling of different bidder categories. It outlines conditions for bid acceptance, the possibility of price band revisions, and the rules concerning minimum subscription levels. Furthermore, it specifies the allocation procedures for different investor categories such as Eligible Employees, QIBs, NIBs, and RIBs, including various reservation and allocation rules.

The section details various rules regarding bidding eligibility, allocation proportions, and procedures under the SEBI ICDR Regulations. It outlines specific rules for eligible employees bidding in the Employee Reservation Portion, including potential discounts. Furthermore, it specifies rules for allocation to different investor categories such as QIBs, Anchor Investors, Mutual Funds, Life Insurance Companies, Pension Funds, Non-Institutional Bidders, and RIBs. The text also discusses various phased implementation of the UPI Mechanism for applications and mandates related to investor grievance redressal and timelines.

The section details various procedural requirements for the offer, including the use of UPI for bidding, different categories of bidders such as Anchor Investors, Qualified Institutional Buyers (QIBs), and Eligible Employees, and rules concerning the submission and processing of bids. It specifies conditions for various investor types regarding the forms they can use, the required documentation, and the acceptance of bids based on the timing relative to the bid/offer closing date. Furthermore, it outlines restrictions on who can participate in the offer, such as promoter groups, and rules regarding the handling of bids from different entities.

This section details various requirements and restrictions concerning the participation of different investor categories in the offer, including FPIs, VCFs, AIFs, limited liability partnerships, banking companies, insurance companies, and various funds. It outlines specific documentation, such as certificates of registration, required for various bidders, and investment limits prescribed by different regulations like SEBI FPI Regulations, FEMA Rules, and insurance regulations. Furthermore, it specifies rules for handling multiple bids, ensuring proper identification of investors, and compliance with various Know Your Customer (KYC) norms and documentation requirements for electronic bidding systems.

This section details various procedural requirements and warnings related to bidding and offer processes, primarily concerning documentation, payment methods, and adherence to regulations. It outlines stipulations for attestations of signatures, requirements for investor status and category indication in forms, and compliance checks for bids submitted by residents outside India. Furthermore, it specifies rules regarding the use of UPI for bidding, the handling of funds blocked under the ASBA process, and various prohibitions against certain bidding practices such as using cash or incorrect documentation.

The section outlines various conditions and rights related to the issuance of Equity Shares, including provisions for withdrawing offers and requirements for filing fresh offer documents with SEBI. It details restrictions on the transfer of shares between Indian residents and non-residents, and various regulations concerning foreign investment and the transfer of ownership of foreign direct investment in Indian entities. Furthermore, it specifies that the Equity Shares are not registered under the U.S. Securities Act and may have restrictions on where they can be offered or sold.

This section summarizes related party transactions for the financial years ended March 31, 2026, March 31, 2025, and March 31, 2024, as required by Ind AS 24 and SEBI ICDR Regulations. The disclosed transactions involve various entities, including rights issues, bonus issues, and services provided by fellow subsidiaries. Key transactions include significant sales of services to subsidiaries and various interest income and expense transactions.

This section primarily details various compliance and procedural aspects related to the filing and offering process, including the identification of statutory auditors, designated intermediaries, and the book-building process. It lists the statutory auditors as S.R. Batliboi & Associates LLP and mentions the bankers to the company, HDFC Bank Limited. Furthermore, it outlines various lists and procedures concerning Syndicate Banks, Registered Brokers, Registrar and Share Transfer Agents, and Collecting Depository Participants, as well as rules for different types of bidders (like QIBs, RIBs, and Anchor Investors) in the ASBA process. The text also covers the process for determining the offer price and the subsequent steps for filing the prospectus and obtaining listing approvals.

This section primarily discusses the underwriting commitments for the equity shares, rather than detailing specific related party transactions. It mentions that the underwriting commitments are indicative and will be finalized after the Offer Price is determined and the allocation of equity shares is made according to SEBI ICDR Regulations. The Board of Directors approved the acceptance and execution of the Underwriting Agreement. It is noted that underwriters are severally responsible for ensuring payment for the equity shares allocated to investors, and in case of default, the underwriter must procure purchasers for the defaulted amount.

The company's Board comprises nine Directors, including the Chief Executive Officer and Managing Director, and eight Non-Executive Directors, with three being Independent Directors. The Board composition adheres to corporate governance requirements. The document details the particulars of the Board members, including their designations, terms, and other directorships. Specific information is provided regarding the appointment and remuneration of the Managing Director and CEO, Patrice Rochelle Wolfe, as well as the sitting fees and remuneration entitlements for the various types of Directors.

The document outlines various restrictions concerning the financial dealings and interests of the company's directors, including prohibitions on certain transactions with the company and its directors. It specifies that no such amounts or benefits have been paid or given to directors within the preceding two years, except as disclosed in related party transactions. Furthermore, it details exclusions regarding directors' directorships in listed companies and clarifies that no directors have been declared as Wilful Defaulters or Fraudulent Borrowers by financial institutions. The text also details the composition and mandate of various Board committees, such as the Audit Committee and the Nomination and Remuneration Committee.

The management section details various committees and key personnel within the company structure. It outlines the functions and composition of the Nomination and Remuneration Committee, the Stakeholders Relationship Committee, the Risk Management Committee, and the Corporate Social Responsibility Committee, referencing their mandates under relevant laws and regulations. Furthermore, it provides detailed profiles for several Key Managerial Personnel, including the Managing Director and CEO, the Chief Financial Officer, the Company Secretary and Compliance Officer, and several Senior Management members employed by the subsidiary.

The management section details key personnel, including the Chief Information Officer and Chief People Officer, along with various disclosures regarding their appointments, remuneration, and relationships. It also outlines the promoter group, which includes BCP Asia II HoldCo VIII Pte. Ltd., and provides information on the history of the promoter's acquisition of the company. The section also covers various aspects of financial and corporate dealings, such as shareholding, contingent compensation, and arrangements with third parties.

The company's dividend distribution policy is subject to Board recommendation and shareholder approval, in accordance with the Articles of Association and Companies Act. The Board also has the absolute power to declare interim dividends as per the Companies Act. Dividend declaration will depend on internal factors such as profits, accumulated reserves, liquidity, expected capital expenditure, and the cost of raising funds. External factors, including the state of the economy, capital markets, and regulatory changes, will also influence dividend decisions. The company retains the right to retain all future earnings for business expansion or other purposes, and there is no guarantee of future dividend payments. The company has not declared or paid any dividend in the last three fiscal years.

The Articles of Association detail the framework for the company's operations, having been approved by the shareholders. The provisions cover various aspects concerning the company's structure, including definitions, the scope of the applicable laws, and the types of share capital that can be issued. The Articles grant the Board certain powers regarding the issuance and disposal of shares, and the company has the power to modify its share capital structure through resolutions. Furthermore, the Articles address the handling of new capital, the division or consolidation of shares, and specific procedures for the further issuance of shares.

This section details various provisions concerning the issuance and allotment of shares, including the ability of the Board to issue further shares, the treatment of rights conferred upon existing shareholders, and the procedures for accepting applications for shares. It also outlines rules regarding the return on allotments, the nature of money due on shares, and provisions for installments. Furthermore, the articles cover mechanisms for varying shareholder rights, the issuance of preference shares, and the power of the Board to amalgamate the company. A significant part of the section deals with the process of selling shares, including the company's lien rights, the treatment of proceeds from sales, and the conditions under which shares may be forfeited due to non-payment of calls or dues.

The provisions detail various aspects related to the forfeiture of shares, including the liability of former members and the rights of the Board to enforce payments. The articles also cover the transfer and transmission of shares, including provisions for dematerialized forms and the power of the Board to close registers. Furthermore, the text outlines procedures for general meetings, including the notice periods, quorum requirements, and the nature of business transacted in different types of meetings.

This section details various procedural aspects concerning the conduct of General Meetings and Board operations. It covers the roles of the Chairman, procedures for adjournment, rules regarding voting, and the use of various voting methods like polls and postal ballots. Furthermore, it outlines specific voting rights for members, provisions for appointing directors, rules on director tenure and retirement, and the conduct of Board meetings, including quorum requirements and decision-making processes.

The provisions detail various aspects of corporate governance, including the election of a Chairman for the Board and Committees, powers of the Board and Directors, delegation of powers, and the validity of acts done by the Board or committees. The articles also cover the handling of negotiable instruments, the power to borrow money, and the conditions under which borrowed funds can be raised by shareholders. Furthermore, there are stipulations regarding the appointment and removal of Managing Directors, the duties of such directors, and the appointment of key managerial personnel. The section also outlines rules for dividend declaration, the handling of unpaid dividends, and the apportionment of profits for dividends.

The provisions detail various aspects related to the inspection of company records, the service of legal documents, and the disclosure of material contracts. Certain documents, including agreements for an offer, various incorporation certificates, board resolutions, and agreements with various entities, are listed as material contracts for inspection. These materials are available for inspection at the Registered and Corporate Office during specific hours and on the company's website until the Bid/Offer Closing Date.

This section primarily details various consents, reports, and agreements provided by different parties, including auditors, legal counsel, and consultants, related to the financial information and documentation in the Draft Red Herring Prospectus. It includes references to various reports concerning financial statements, special tax benefits, and industry overviews, along with consents from directors and various entities to include their names in the prospectus. Furthermore, it mentions agreements between the company, NSDL, and the Registrar to the Offer, as well as in-principle listing approvals from stock exchanges.

The provided section primarily consists of multiple declarations signed by various directors certifying compliance with various laws and regulations. These declarations affirm that all relevant provisions of the Companies Act and rules issued by the Government of India or SEBI have been complied with. Furthermore, the signatories certify that no statement, disclosure, or undertaking in the Updated Draft Red Herring Prospectus is contrary to the provisions of the Companies Act, SCRA, SCRR, and SEBI Act, as amended, or the rules and guidelines issued thereunder.

This section primarily contains declarations and certifications from the company and its promoter regarding the compliance of the Draft Red Herring Prospectus with various laws and regulations. The declarations confirm that all relevant provisions of the Companies Act and SEBI regulations have been complied with, and that all statements made in the prospectus are true and correct. Furthermore, the promoter confirms the accuracy of statements related to themselves and the offered shares, while disclaiming responsibility for other statements made in the document.